Nanogenics

Nanogenics Limited (formely Ryboquin (presumed to be the subsidiary of Ectopharma Ltd)) is a privately owned virtual pharmaceutical company in Scotland that inlicenses the LipTide siRNa technology from Nanogenics and focus on commercialising patented technologies in the area of human cancer medicine. In July 2018, following the acquisition of Nanogenics Solutions, the company was renamed as "Nanogenics Limited".In July 2018, Ryboquin acquired Nanogenics Solutions, to form a new platform comapany called "Nanogenics Limited", to advance all forms of gene therapy